バイオマーカー検査サービス市場規模、シェア、動向分析レポート：サービス別、用途別、タイプ別、最終用途別、地域別、セグメント別予測、2025年～2030年

バイオマーカー検査サービス市場の成長と動向

Grand View Research, Inc.の最新レポートによると、バイオマーカー検査サービスの世界市場規模は、2025～2030年にかけてCAGR 8.59%を記録し、2030年までに10億6,000万米ドルに達すると予測されています。

医薬品研究開発への投資の増加、がん治療に用いられる精密医療への需要の増加、バイオマーカー検査の需要を促進する感染症や慢性疾患の負担増などが、市場の成長を促進する主要要因の一部です。

過去5年間、臨床検査は一貫して増加しています。例えば、ClinicalTrials.govによると、2018年には26万2,298件以上の臨床検査が登録されたが、2022年9月時点では39万9,518件以上の臨床検査が登録されています。臨床研究への資金提供の増加により、臨床検査は今後数年で改善すると予想されます。これにより、創薬研究活動の需要が高まり、ポストパンデミック期におけるバイオマーカー検査の需要を支えることが期待されます。

バイオマーカーの使用による医薬品のFDA承認率は、年々向上しています。例えば、2016年には、医療検査にバイオマーカーを使用した26以上の臨床検査がFDAによって承認されたが、2019年には、医療検査にバイオマーカーを使用した36の臨床検査がFDAによって承認されました。臨床検査は、体内での薬の作用に関する情報を提供するため、薬の承認プロセスを迅速化するため、薬の承認にバイオマーカー関連データを必要とするようになりました。このため、予測期間中はバイオマーカー検査の需要が高まると予想されます。

さまざまなバイオ医薬品企業が、バイオマーカー検査を通じてがん患者の診断率を向上させる取り組みを行っています。例えば、2021年4月、バイオ医薬品企業のAmgenはバイオマーカーアシストプログラムを開始しました。このプログラムによると、転移性（ステージIV）の非小細胞肺がん（NSCLC）患者にはバイオマーカー検査が提供され、標的治療に役立つがん遺伝子バイオマーカーの存在が確認されました。市場参入企業によるこうした取り組みは、市場の成長を後押しするとみられます。

IQVIAのオンコロジー動向に関する報告書によると、がんの臨床検査は過去10年間増加し続けています。例えば、2011年には1,242件の臨床検査が登録され、2021年時点では2,335件の臨床検査が登録されています。がんを対象とした臨床検査の数は、有病率の増加によりさらに増加すると予想されます。研究において薬剤の有効性を検査するためにバイオマーカーを使用する、がんを対象に設計された標的療法の需要が増加しています。今後数年間におけるがん研究の増加は、がん検査用に設計されたバイオマーカーの需要を押し上げ、その結果、ポストパンデミック期の市場を支えることになると予想されます。

バイオマーカー検査サービス市場レポートハイライト

• バイオマーカーアッセイの開発と検証セグメントは、2024年に45.77%の最大シェアを占める見込み。疾患の診断におけるコンパニオン診断の需要の高まりが、バイオマーカーアッセイ開発＆バリデーションサービスの需要を支えるものと予測されます。
• 最終用途別では、製薬・バイオテクノロジー企業が2024年に45.45%の最大シェアを占めました。
• 北米は2024年に46.23%の最大シェアを占めました。研究のための技術的に進んだインフラと公的機関による研究投資の増加が、この地域の市場成長を支えています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオマーカー検査サービス市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 補助市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• バイオマーカー検査サービス市場：分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 バイオマーカー検査サービス市場：サービス別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオマーカー検査サービス市場変動分析
• 世界のバイオマーカー検査サービス市場規模と動向分析、サービス別、2018～2030年
• バイオマーカーアッセイの開発と検証
• フローサイトメトリー
• その他

第5章 バイオマーカー検査サービス市場：用途別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオマーカー検査市場変動分析
• 世界のバイオマーカー検査サービス市場規模と動向分析、用途別、2018～2030年
• 腫瘍学
• 医薬品の発見と開発
• その他

第6章 バイオマーカー検査サービス市場：タイプ別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオマーカー検査サービス市場の変動分析
• 世界のバイオマーカー検査サービス市場規模と動向分析、タイプ別、2018～2030年
• 分子バイオマーカー
• 細胞バイオマーカー

第7章 バイオマーカー検査サービス市場：最終用途別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオマーカー検査サービス市場の変動分析
• 世界のバイオマーカー検査サービス市場規模と動向分析、最終用途別、2018～2030年
• 製薬・バイオテクノロジー企業
• 研究機関
• CRO

第8章 バイオマーカー検査サービス市場：地域別、推定・動向分析

• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • インドネシア
  • マレーシア
  • シンガポール
  • 台湾
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • コロンビア
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート
  • イスラエル

第9章 競合情勢

• 参入企業
• 戦略マッピング
• 企業市況分析、2024年
• 企業プロファイル
  • Bio Agilytix Labs
  • Eurofins Scientific
  • SGS SA.
  • Charles River Laboratories
  • LabCorp
  • Thermo Fisher Scientific Inc.（PPD, Inc.）
  • ICON Plc
  • IQVIA
  • Syneos Health
  • Intertek Group Plc

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 4 Global Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 5 Global Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 6 Global Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 7 Global Biomarker Testing Services, by Region, 2018 - 2030 (USD Million)
• Table 8 North America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 10 North America Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 11 North America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 12 North America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 13 U.S. Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 14 U.S. Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 15 U.S. Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 16 U.S. Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 17 Canada Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 18 Canada Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 19 Canada Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 20 Canada Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 21 Mexico Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 22 Mexico Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 23 Mexico Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 24 Mexico Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 25 Europe Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
• Table 26 Europe Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 27 Europe Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 28 Europe Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 29 Europe Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 30 Germany Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 31 Germany Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 32 Germany Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 33 Germany Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 34 UK Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 35 UK Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 36 UK Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 37 UK Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 38 France Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 39 France Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 40 France Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 41 France Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 42 Italy Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 43 Italy Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 44 Italy Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 45 Italy Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 46 Spain Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 47 Spain Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 48 Spain Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 49 Spain Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 50 Denmark Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 51 Denmark Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 52 Denmark Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 53 Denmark Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 54 Sweden Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 55 Sweden Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 56 Sweden Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 57 Sweden Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 58 Norway Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 59 Norway Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 60 Norway Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 61 Norway Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 67 China Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 68 China Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 69 China Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 70 China Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 71 Japan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 72 Japan Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 73 Japan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 74 Japan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 75 India Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 76 India Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 77 India Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 78 India Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 79 South Korea Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 80 South Korea Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 81 South Korea Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 82 South Korea Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 83 Australia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 84 Australia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 85 Australia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 86 Australia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 87 Thailand Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 88 Thailand Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 89 Thailand Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 90 Thailand Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 91 Indonesia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 92 Indonesia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 93 Indonesia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 94 Indonesia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 95 Malaysia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 96 Malaysia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 97 Malaysia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 98 Malaysia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 99 Singapore Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 100 Singapore Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 101 Singapore Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 102 Singapore Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 103 Taiwan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 104 Taiwan Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 105 Taiwan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 106 Taiwan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 107 Latin America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
• Table 108 Latin America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 109 Latin America Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 110 Latin America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 111 Latin America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 112 Brazil Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 113 Brazil Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 114 Brazil Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 115 Brazil Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 116 Argentina Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 117 Argentina Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 118 Argentina Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 119 Argentina Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 120 Middle East & Africa Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
• Table 121 Middle East & Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 122 Middle East & Africa Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 123 Middle East & Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 124 Middle East & Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 125 South Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 126 South Africa Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 127 South Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 128 South Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 129 Saudi Arabia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 130 Saudi Arabia Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 131 Saudi Arabia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 133 UAE Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 134 UAE Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 135 UAE Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 136 UAE Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 137 Kuwait Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 138 Kuwait Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 139 Kuwait Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 140 Kuwait Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
• Table 141 Israel Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
• Table 142 Israel Biomarker Testing Services, by Application, 2018 - 2030 (USD Million)
• Table 143 Israel Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
• Table 144 Israel Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Biomarker Testing Services, Market Segmentation
• Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 9 Porter's Five Forces Analysis
• Fig. 10 PESTEL Analysis
• Fig. 11 Regional Marketplace: Key Takeaways
• Fig. 12 Global Biomarker Testing Services, for Biomarker Assay Development & Validation, 2018 - 2030 (USD Million)
• Fig. 13 Global Biomarker Testing Services: Service Key Takeaways
• Fig. 14 Global Biomarker Testing Services: Service Movement Analysis
• Fig. 15 Global Biomarker Testing Services, for Flow Cytometry, 2018 - 2030 (USD Million)
• Fig. 16 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
• Fig. 17 Global Biomarker Testing Services: Application Key Takeaways
• Fig. 18 Global Biomarker Testing Services: Application Movement Analysis
• Fig. 19 Global Biomarker Testing Services, for Oncology, 2018 - 2030 (USD Million)
• Fig. 20 Global Biomarker Testing Services, for Drug Discovery & Development, 2018 - 2030 (USD Million)
• Fig. 21 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
• Fig. 22 Global Biomarker Testing Services: Type Key Takeaways
• Fig. 23 Global Biomarker Testing Services: Type Movement Analysis
• Fig. 24 Global Biomarker Testing Services, for Molecular Biomarkers, 2018 - 2030 (USD Million)
• Fig. 25 Global Biomarker Testing Services, for Cellular Biomarkers, 2018 - 2030 (USD Million)
• Fig. 26 Global Biomarker Testing Services: End Use Key Takeaways
• Fig. 27 Global Biomarker Testing Services: End Use Movement Analysis
• Fig. 28 Global Biomarker Testing Services, for Pharmaceutical and Biotechnology Companies, 2018-2030, (USD Million
• Fig. 29 Global Biomarker Testing Services, for Research Institutes, 2018 - 2030 (USD Million)
• Fig. 30 Global Biomarker Testing Services, for CROs, 2018 - 2030 (USD Million)
• Fig. 31 Regional Outlook, 2024 & 2030
• Fig. 32 North America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 33 US Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Canada Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Mexico Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Europe Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Germany Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 UK Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 39 France Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Italy Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Spain Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Denmark Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Sweden Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Norway Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Asia Pacific Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Japan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 47 China Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 48 India Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Australia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 50 South Korea Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Thailand Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Indonesia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Malaysia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Singapore Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Taiwan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Latin America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Brazil Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Argentina Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Middle East and Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 60 South Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Saudi Arabia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 62 UAE Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Kuwait Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Israel Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Biomarker Testing Services Market Growth & Trends:

The global biomarker testing services market size is expected to reach USD 1.06 billion by 2030, registering a CAGR of 8.59% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights:

• The biomarker assay development & validation segment by service was expected to hold the largest share of 45.77% in 2024. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
• Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 45.45% in 2024, owing to the rising investment in R&D by these companies
• North America held the largest share of 46.23% in 2024, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. Type Segment
  • 1.2.4. End Use Segment
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Biomarker Testing for Cancer Detection
    • 3.2.1.2. Increasing R&D Activities
    • 3.2.1.3. Growing Burden of Chronic and Infectious Diseases Supporting Demand for Biomarker Testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Capital Investments and Lengthy Timelines for Biomarker Development
• 3.3. Biomarker Testing Services Market: Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Testing Services Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biomarker Testing Service Market Movement Analysis
• 4.3. Global Biomarker Testing Service Market Size & Trend Analysis, by services, 2018 to 2030 (USD Million)
• 4.4. Biomarker Assay Development & Validation
  • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 4.5. Flow Cytometry
  • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Testing Services Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biomarker Testing Application Market Movement Analysis
• 5.3. Global Biomarker Testing Service Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 5.5. Drug Discovery & Development
  • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Testing Services Market: Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Biomarker Testing Services Market Movement Analysis
• 6.3. Global Biomarker Testing Services Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Molecular Biomarkers
  • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 6.5. Cellular Biomarkers
  • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biomarker Testing Services Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Biomarker Testing Services Market Movement Analysis
• 7.3. Global Biomarker Testing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 7.5. Research Institutes
  • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 7.6. CROs
  • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Biomarker Testing Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Global Regional Market Snapshot
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Scenario
    • 8.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Scenario
    • 8.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Scenario
    • 8.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Scenario
    • 8.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Scenario
    • 8.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Scenario
    • 8.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Scenario
    • 8.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Scenario
    • 8.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Scenario
    • 8.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Scenario
    • 8.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Scenario
    • 8.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Scenario
    • 8.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.3. Japan
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Scenario
    • 8.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Scenario
    • 8.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Scenario
    • 8.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Scenario
    • 8.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Scenario
    • 8.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.8. Indonesia
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Scenario
    • 8.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.9. Malaysia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Scenario
    • 8.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.10. Singapore
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Scenario
    • 8.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6.11. Taiwan
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Scenario
    • 8.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Scenario
    • 8.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Scenario
    • 8.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7.4. Colombia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Scenario
    • 8.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Scenario
    • 8.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Scenario
    • 8.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Scenario
    • 8.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Scenario
    • 8.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8.6. Israel
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Scenario
    • 8.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Bio Agilytix Labs
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Eurofins Scientific
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. SGS SA.
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Charles River Laboratories
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. LabCorp
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Thermo Fisher Scientific Inc. (PPD, Inc.)
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. ICON Plc
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. IQVIA
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Syneos Health
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Intertek Group Plc
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives